scispace - formally typeset
M

Marcello Montagni

Researcher at University of Parma

Publications -  39
Citations -  839

Marcello Montagni is an academic researcher from University of Parma. The author has contributed to research in topics: Allergy & Anaphylaxis. The author has an hindex of 11, co-authored 34 publications receiving 626 citations.

Papers
More filters
Journal ArticleDOI

Meteorological conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the World Allergy Organization

TL;DR: Global warming is expected to affect the start, duration, and intensity of the pollen season, and the rate of asthma exacerbations due to air pollution, respiratory infections, and/or cold air inhalation, and other conditions on the other hand.
Journal ArticleDOI

Extended IgE profile based on an allergen macroarray: a novel tool for precision medicine in allergy diagnosis

TL;DR: Evaluating the characteristics of the newly developed Allergy Explorer (ALEX), a macroarray containing both extracted “whole” allergens and molecular components, found it to be a novel tool for describing the IgE profile in a PM setting.
Journal ArticleDOI

Bilastine: new insight into antihistamine treatment

TL;DR: Results show that bilastine meets current EAACI/ARIA criteria for medications used in the treatment of AR and chronic urticaria, and the review of the literature indicates that once-daily treatment with bilastines 20 mg was effective in managing symptoms and improving patient’s quality of life.
Journal ArticleDOI

Anaphylaxis and cardiovascular diseases: a dangerous liaison.

TL;DR: A better understanding of the mechanisms leading to cardiac mast cell activation and the effects of mast cell mediators on cardiovascular system can help improve the prevention and treatment of anaphylaxis.
Journal ArticleDOI

Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.

TL;DR: Though some similarities between RCTs and R-L studies strengthen omalizumab efficacy and safety outcomes, significant differences concerning study population features, follow-up duration, local adverse events and drop-out rate for treatment inefficacy emerge between the two study categories.